- Home
- SKIL vs TLSI Comparison
SKIL vs TLSI Comparison
Compare SKIL & TLSI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SKIL
- TLSI
- Stock Information
- Founded
- SKIL 1998
- TLSI 2010
- Country
- SKIL United States
- TLSI United States
- Employees
- SKIL N/A
- TLSI N/A
- Industry
- SKIL Computer Software: Prepackaged Software
- TLSI Medical Specialities
- Sector
- SKIL Technology
- TLSI Health Care
- Exchange
- SKIL Nasdaq
- TLSI Nasdaq
- Market Cap
- SKIL 142.2M
- TLSI 160.4M
- IPO Year
- SKIL N/A
- TLSI N/A
- Fundamental
- Price
- SKIL $22.07
- TLSI $5.74
- Analyst Decision
- SKIL Strong Buy
- TLSI Strong Buy
- Analyst Count
- SKIL 1
- TLSI 6
- Target Price
- SKIL $50.00
- TLSI $11.75
- AVG Volume (30 Days)
- SKIL 37.4K
- TLSI 57.4K
- Earning Date
- SKIL 04-14-2025
- TLSI 05-14-2025
- Dividend Yield
- SKIL N/A
- TLSI N/A
- EPS Growth
- SKIL N/A
- TLSI N/A
- EPS
- SKIL N/A
- TLSI N/A
- Revenue
- SKIL $530,994,000.00
- TLSI $29,431,000.00
- Revenue This Year
- SKIL $4.49
- TLSI $55.08
- Revenue Next Year
- SKIL $6.77
- TLSI $50.75
- P/E Ratio
- SKIL N/A
- TLSI N/A
- Revenue Growth
- SKIL N/A
- TLSI 58.99
- 52 Week Low
- SKIL $5.09
- TLSI $3.50
- 52 Week High
- SKIL $34.43
- TLSI $10.24
- Technical
- Relative Strength Index (RSI)
- SKIL 56.77
- TLSI 59.91
- Support Level
- SKIL $16.71
- TLSI $5.23
- Resistance Level
- SKIL $22.31
- TLSI $5.66
- Average True Range (ATR)
- SKIL 1.75
- TLSI 0.34
- MACD
- SKIL 0.67
- TLSI 0.03
- Stochastic Oscillator
- SKIL 97.00
- TLSI 92.94
About SKIL Skillsoft Corp.
Skillsoft Corp is a leader in corporate digital learning. The company's segment includes Content & Platform and Instructor-Led Training. The Content & Platform business engages in the sale, marketing and delivery of its content learning solutions, in areas such as Leadership and Business, Technology and Developer and Compliance. The Instructor-Led Training business offers training solutions covering information technology and business skills for corporations and their employees. The majority of revenue is from the Content & Platform segment.
About TLSI TriSalus Life Sciences Inc.
TriSalus Life Sciences Inc is engaged in the research, development, and sales of innovative drug delivery technology and immune-oncology therapeutics to improve outcomes in difficult-to-treat liver and pancreatic cancer. It is developing and marketing two product lines Pressure Enabled Drug Delivery (PEDD) infusion systems, in use today, and an investigational agent, nelitolimod (SD-101), which shows potential to enhance immune system response in the treatment of hepatocellular cancer, pancreatic cancer and other liver solid tumors. TriNav is the newest therapy delivery device with SmartValve technology for the proprietary PEDD approach.